Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Merck Millipore Launches PDReady™ Monoclonal Antibodies Kit

Published: Tuesday, December 11, 2012
Last Updated: Tuesday, December 11, 2012
Bookmark and Share
Integrates small-scale purification devices, process development protocols and technical support for rapid and efficient downstream process development.

Merck Millipore has launched its PDReady™ for Monoclonal Antibodies (MAbs) Kit for accelerating process development timelines.

The kit is based on a robust process development template using technologies for each purification operation.

Every step within the template uses a technology already proven to successfully purify MAbs, allowing biopharmaceutical manufacturers to rapidly develop a reliable purification process that delivers high purity and yield.

The PDReady™ for MAbs Kit reduces the complexity of process development by providing a single integrated package including purification devices, precise protocols to guide process development, specific recommendations for required laboratory tools, support from Merck Millipore technical experts, and equipment such as the Cogent® µScale that is loaned to the customer.

Each unit operation within the template is designed for convenient scaling from bench to clinic. By employing a proven template for MAb purification, the necessary experimentation for process development is drastically reduced, saving time, money and effort, while still developing a robust process.

"The PDReady™ for MAbs Kit leverages Merck Millipore's proven technologies to deliver a template for rapid and efficient downstream process development," said Vin Donovan, Vice President of Biopharm Process Solutions.

Donovan continued, "Our experience with these technologies in monoclonal antibody processes allows us to establish known process parameters, drastically reducing the experimentation required to achieve drug purity and yield targets. This speeds the time to clinic and ultimately commercial-scale production."

Purification unit operations within the PDReady™ for MAbs Kit include:
• Clarification - Millistak+® Pod Filter System
- Robust clarification in an easy-to-use format
• Affinity Chromatography - ProSep® Media
- Designed for cost-effective purification of high titer therapeutic antibodies
• Cation Exchange Chromatography - Fractogel® Media
- Provides reliability with optimal yields and efficient purification
• Anion Exchange Chromatography - ChromaSorb™ Membrane Absorber
- Provides the greatest levels of impurity binding at the highest salt concentrations for monoclonal antibodies
• Virus Filtration - Viresolve® Filters
- Robustly retains viruses while ensuring maximum product recovery
• Ultrafiltration - Pellicon® 3 Cassettes
- Tangential flow filtration device of choice for demanding filtration processes, including higher operating pressures, temperatures and caustic cleaning regimes
• Sterile Filtration (including buffers) - Millipore Express® Filters
- Provides sterility assurance, broad chemical compatibility, high flow rates and exceptionally high capacity
• Cogent® µScale TFF System
- Easy-to-use, semi-automated bench top TFF system for micro-scale process development and everyday low-volume ultrafiltration/diafilitration


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Merck Millipore Announces Agreement with Precision Biologics
Merck Millipore services include design and development of cost-effective process to deliver high yield and productivity.
Thursday, February 05, 2015
Merck Millipore Partners with Gyros
Partnership to develop, manufacture and commercialize kits on the Gyrolab™ immunoassay platform.
Tuesday, July 16, 2013
Merck Millipore Announces Partnership with NIH Consortium
Adds more than 140 peer-validated neuroscience-specific monoclonal antibodies to portfolio.
Tuesday, October 16, 2012
Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
Antibody Drug Shows Promise in HIV Treatment
Researchers are a step closer to an alternative HIV treatment that has the potential for lasting effects and less frequent dosing.
Targeting Autoimmunity
Researchers have developed a strategy to treat a rare autoimmune disease which could lead to treatments of other autoimmune diseases.
Flu Vaccine May Reduce Death Risk of Type 2 Diabetes
New research suggests that a new flu vaccine may reduce probability of type 2 diabetes patients being hospitalised with stroke and heart failure.
Gut Bacteria Older than Human Species
Some bacteria have lived in the human gut since before we were human, suggesting evolution could have a larger role inhuman bacterial makeup.
Evidence of Mosquito Transmitting Zika
A direct link between the Yellow fever mosquito and Zika transmission has been found following investigation into selective mosquito control.
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Three-Drug Combinations Counter Antibiotic Resistance
Research shows that combinations of three different antibiotics can treat resistant bacteria, even if they are ineffective independently.
Mapping Zika’s Routes to Developing Fetus
UC researchers show how Zika virus travels from a pregnant woman to her fetus, and also identified a drug that could stop it.
Treating HIV with Cancer-Fighting Gene Shows Promise
A type of gene immunotherapy that has shown promising results against cancer could also be used against HIV.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!